Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1984 2
1985 1
1987 1
1988 1
1989 5
1990 1
1991 3
1992 5
1993 9
1994 7
1995 3
1996 7
1997 3
1998 10
1999 8
2000 6
2001 8
2002 4
2003 8
2004 5
2005 9
2006 7
2007 8
2008 9
2009 1
2010 8
2011 7
2012 3
2013 5
2014 5
2015 11
2016 12
2017 6
2018 7
2019 8
2020 2
2021 6
2022 6
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

199 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Wilms Tumor 1 Gene Syndromes"
Page 1
Alternative RNA splicing defects in pediatric cancers: new insights in tumorigenesis and potential therapeutic vulnerabilities.
Venkataramany AS, Schieffer KM, Lee K, Cottrell CE, Wang PY, Mardis ER, Cripe TP, Chandler DS. Venkataramany AS, et al. Ann Oncol. 2022 Jun;33(6):578-592. doi: 10.1016/j.annonc.2022.03.011. Epub 2022 Mar 23. Ann Oncol. 2022. PMID: 35339647 Free article. Review.
RESULTS: Published dysregulated splicing events can be categorized as exon inclusion, exon exclusion, splicing factor up-regulation, or splice site alterations. We observe these phenomena in cancer predisposition syndromes (Lynch syndrome, Li-Fraumeni synd …
RESULTS: Published dysregulated splicing events can be categorized as exon inclusion, exon exclusion, splicing factor up-regulation, or spli …
Wilms' tumor gene 1: lessons from the interface between kidney development and cancer.
Torban E, Goodyer P. Torban E, et al. Am J Physiol Renal Physiol. 2024 Jan 1;326(1):F3-F19. doi: 10.1152/ajprenal.00248.2023. Epub 2023 Nov 2. Am J Physiol Renal Physiol. 2024. PMID: 37916284 Review.
In 1990, mutations of the Wilms' tumor-1 gene (WT1), encoding a transcription factor in the embryonic kidney, were found in 10-15% of Wilms' tumors; germline WT1 mutations were associated with hereditary syndromes involving glomerular and …
In 1990, mutations of the Wilms' tumor-1 gene (WT1), encoding a transcription factor in the embryonic kidney, we …
Heterogeneity of human WT1 gene.
Bielińska E, Matiakowska K, Haus O. Bielińska E, et al. Postepy Hig Med Dosw (Online). 2017 Jul 11;71(0):595-601. doi: 10.5604/01.3001.0010.3840. Postepy Hig Med Dosw (Online). 2017. PMID: 28791954 Review.
The molecular basis of diseases such as Wilms tumor, WAGR, Denys-Drash or Frasier syndromes are congenital WT1 mutations, while somatic mutations of this gene occur in acute and chronic myeloid leukemia, myelodysplastic syndrome and also in some …
The molecular basis of diseases such as Wilms tumor, WAGR, Denys-Drash or Frasier syndromes are congenital WT1 mutation …
Spontaneous xenogeneic GvHD in Wilms' tumor Patient-Derived xenograft models and potential solutions.
Monzavi SM, Muhammadnejad A, Behfar M, Khorsand AA, Muhammadnejad S, Kajbafzadeh AM. Monzavi SM, et al. Animal Model Exp Med. 2022 Dec;5(4):389-396. doi: 10.1002/ame2.12254. Epub 2022 Jun 20. Animal Model Exp Med. 2022. PMID: 35726155 Free PMC article.
Wilms' tumor (WT) has not been recognized as a lymphocyte-predominant tumor. ...Laboratory and histopathologic evaluations revealed lymphoid infiltrates positively immunostained with anti-human CD3 and CD8 antibodies in the xenografts and primary tumor …
Wilms' tumor (WT) has not been recognized as a lymphocyte-predominant tumor. ...Laboratory and histopathologic evaluati …
Lessons from our children.
Donaldson SS. Donaldson SS. Int J Radiat Oncol Biol Phys. 1993 Aug 1;26(5):739-49. doi: 10.1016/0360-3016(93)90487-g. Int J Radiat Oncol Biol Phys. 1993. PMID: 8344841 Free article. Review.
Specific pediatric cancers, such as retinoblastoma, have led to the recognition of tumor suppressor genes, now also observed among adult tumors including sarcomas, breast, lung, and bladder cancer. ...For some specific childhood tumors such as rhabdomyosarcom …
Specific pediatric cancers, such as retinoblastoma, have led to the recognition of tumor suppressor genes, now also observe …
WT1 and glomerular diseases.
Niaudet P, Gubler MC. Niaudet P, et al. Pediatr Nephrol. 2006 Nov;21(11):1653-60. doi: 10.1007/s00467-006-0208-1. Epub 2006 Aug 23. Pediatr Nephrol. 2006. PMID: 16927106 Review.
Patients with Denys-Drash syndrome present with early nephrotic syndrome with diffuse mesangial sclerosis progressing rapidly to end-stage renal failure, male pseudohermaphroditism, and Wilms' tumor. ...Germline intronic mutations leading to the loss o …
Patients with Denys-Drash syndrome present with early nephrotic syndrome with diffuse mesangial sclerosis progressing rapidly …
Wilms' tumor 1 expression combined with genetic mutations for prognostic assessment in MDS.
Pan D, Zhao W, Jiang Q, Yin C, He H, Liao L, Ye J, Dai M. Pan D, et al. Leuk Lymphoma. 2023 Apr;64(4):856-864. doi: 10.1080/10428194.2023.2185086. Epub 2023 Mar 11. Leuk Lymphoma. 2023. PMID: 36905177
Overexpression of Wilms' tumor (WT1) is frequently observed in myelodysplastic syndrome (MDS), which has been proposed as a prognostic marker. ...In multivariate analysis, higher WT1 expression was a risk factors for OS in EB patients without TP53 muta …
Overexpression of Wilms' tumor (WT1) is frequently observed in myelodysplastic syndrome (MDS), which has been pr …
Ovarian microcystic stromal tumour: from morphological observations to syndromic associations.
Parra-Herran C, McCluggage WG. Parra-Herran C, et al. Histopathology. 2022 May;80(6):898-904. doi: 10.1111/his.14616. Epub 2022 Feb 28. Histopathology. 2022. PMID: 35020947 Review.
Immunohistochemically, this neoplasm is characterized by diffuse nuclear expression of beta-catenin, cyclin D1, Wilms' tumour 1 (WT1) and steroidogenic factor 1 (SF1), as well as diffuse staining with forkhead box ligand 2 (FoxL2) and CD10. ...Rarely, MST is an extracoloni …
Immunohistochemically, this neoplasm is characterized by diffuse nuclear expression of beta-catenin, cyclin D1, Wilms' tumour 1 (WT1) …
The genetic factors contributing to the development of Wilm's tumor and their clinical utility in its diagnosis and prognosis.
Bahrami A, Joodi M, Maftooh M, Ferns GA, M Ahmadi M, Hassanian SM, Avan A. Bahrami A, et al. J Cell Physiol. 2018 Apr;233(4):2882-2888. doi: 10.1002/jcp.26021. Epub 2017 Jul 4. J Cell Physiol. 2018. PMID: 28542793 Review.
Mutations in the Wilm's tumor 1 (WT1) gene are associated with a wide spectrum of renal manifestations, ultimately leading to end-stage kidney failure. ...In this review, we discuss the existing data on the genetic and epigenetic abnormalities that have been describ …
Mutations in the Wilm's tumor 1 (WT1) gene are associated with a wide spectrum of renal manifestations, ultimately leading to …
Phase 1/2 study evaluating the safety and efficacy of DSP-7888 dosing emulsion in myelodysplastic syndromes.
Ueda Y, Usuki K, Fujita J, Matsumura I, Aotsuka N, Sekiguchi N, Nakazato T, Iwasaki H, Takahara-Matsubara M, Sugimoto S, Goto M, Naoe T, Kizaki M, Miyazaki Y, Aakashi K. Ueda Y, et al. Cancer Sci. 2022 Apr;113(4):1377-1392. doi: 10.1111/cas.15245. Epub 2022 Mar 9. Cancer Sci. 2022. PMID: 34932235 Free PMC article. Clinical Trial.
DSP-7888 is an immunotherapeutic cancer vaccine derived from the Wilms' tumor gene 1 (WT1) protein. This phase 1/2 open-label study evaluated the safety and efficacy of DSP-7888 dosing emulsion in patients with myelodysplastic syndromes (MDS). ...Media …
DSP-7888 is an immunotherapeutic cancer vaccine derived from the Wilms' tumor gene 1 (WT1) protein. This phase 1/2 open …
199 results